Entries by Healthcare Team

Fibrocor Therapeutics appoints world-leading nephrologists to Clinical Advisory Board with a focus on its lead indication Alport Syndrome

/in

Fibrocor Therapeutics strengthens its clinical strategy with the appointment of four world-leading nephrology and genetics experts to its Clinical Advisory Board (CAB), reinforcing its scientific leadership in Alport Syndrome. The new CAB brings unparalleled expertise in basement membrane biology, genetic kidney diseases, and glomerular disorders, providing critical guidance as Fibrocor advances its first-in-class pipeline towards […]

Poolbeg Pharma plc – POLB 001 trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

/in

RISE programme led by The University of Manchester and The Christie NHS Foundation Trust and funded in part by MRC grant Poolbeg will act as the lead business partner alongside Johnson & Johnson and other partners 8 December 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that […]

Oncoinvent announces publication of Phase 1 study results for Radspherin® in ovarian cancer in Gynecologic Oncology

/in

Oslo, Norway, 8 December 2025 – Oncoinvent, a clinical stage, radiopharmaceutical company developing innovative treatments for solid cancers, today announced the publication of 12-month data from its Phase 1 study of patients with platinum-sensitive recurrent ovarian cancer and peritoneal carcinomatosis. The results from the first patients have been published in the respected peer-reviewed journal Gynecologic Oncology, […]

Actithera appoints radiopharmaceutical pioneer Dr. Darshan Dalal as Chief Medical Officer

/in

Internationally recognized radiopharmaceutical leader joins Actithera as the lead FAP-targeting asset advances to clinical development and the differentiated pipeline takes shape Brings over 15 years of global oncology and hematology leadership, advancing over 10 radioligands across the development spectrum, from preclinical to Phase III   Oslo, Norway and Cambridge, Massachusetts — 3 December 2025 — […]

Xeltis secures nearly €50m from the European Investment Bank (EIB) and existing shareholders to advance aXess, its vascular access conduit to the market

/in

Up to €37.5m investment from the EIB, consisting of €10m upfront with optionality to further increase by an additional €27.5m €10m investment from existing shareholders including EQT Life Sciences (EQT) and Invest-NL Follows the announcement of excellent EU pivotal trial data highlighting the transformative potential of aXess in hemodialysis treatment European market approval and US […]